NCT04936113: A trial that was reported late by Forte Biosciences, Inc.
This trial has reported, although it was 405 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT04936113 |
|---|---|
| Title | An Open-Label, Multicenter Study to Evaluate Continued Safety of FB-401 for up to 48 Weeks in Children, Adolescent and Adult Subjects (Ages 2 Years and Older) With Mild to Moderate Atopic Dermatitis Previously Enrolled in FB401-01 Phase 2 Study |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 2, 2021 |
| Completion date | Sept. 30, 2021 |
| Required reporting date | Sept. 30, 2022, midnight |
| Actual reporting date | Nov. 9, 2023 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 405 |